Meta-analyses assessing platinum-based regimens versus nonplatinum-based regimens
| Reference | Methodology | Outcome | Trials n | Patients n | Result |
| 92 | IMA | 1 yr survival | 30 | 6504 | Significant (in favour of platinum) |
| 93 | MA | 1 yr risk of death | 11 | 4602 | Significant (in favour of platinum) |
IMA: isolated meta-analysis of the literature; MA: meta-analysis. Regimens are for first-line treatment of nonsmall cell lung cancer.